Publication date: Available online 22 February 2018
Source:Bioorganic & Medicinal Chemistry
Author(s): Til Bahadur Thapa Magar, Seung Hee Seo, Tara Man Kadayat, Hyunji Jo, Aarajana Shrestha, Ganesh Bist, Pramila Katila, Youngjoo Kwon, Eung-Seok Lee
As part of our effort to develop potential topoisomerase IIα (topo IIα) targeting anticancer agents, we systematically designed a new series of hydroxy and chloro-substituted 2,4-diphenyl 5H-chromeno[4,3-b]pyridines. Total eighteen compouds were synthesized and tested for their ablity to inhibit the function of topo I and IIα, and proliferation of human breast (T47D), colorectal (HCT15), and cervix (HeLa) cancer cells. Except compound 11, all of the tested compounds displayed selective topo IIα inhibitory activity. Compounds 8-18, 22, 24, and 25 showed excellent topo IIα inhibitory activity than a positive control, etoposide. Most of the compounds appeared to be superior to reference compounds in their antiproliferative activity. Structure-activity relationship (SAR) study has shown that it is better to place the hydroxyphenyl group at the 4-position of the central pyridine for superior topo IIα inhibition and antiproliferative activity. Similarly, the 3′-, or 4′-hydroxyphenyl substitution at the 2- and 4-positon of pyridine ring is important for better activity than 2′-substitution.
Graphical abstract
http://ift.tt/2F2e0Gh
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου